Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo
Open Access
- 15 September 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (18), 5570-5577
- https://doi.org/10.1158/1078-0432.ccr-06-0367
Abstract
Purpose: The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), has multiple antitumor effects against a variety of human cancers.Keywords
This publication has 23 references indexed in Scilit:
- Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stressBlood, 2006
- Perturbations of the AKT signaling pathway in human cancerOncogene, 2005
- Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2Clinical Cancer Research, 2005
- Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non–small cell lung cancerSurgery, 2005
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid CancerClinical Cancer Research, 2005
- Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell linesExperimental Hematology, 2005
- Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosisCancer, 2004
- Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer CellsClinical Cancer Research, 2004
- Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells.JCI Insight, 1986